Sijo Parekattil, MD

In this Industry Perspective, Sijo Parekattil, MD, reviews how the CLS-TRANBERG system is used for image-guided focal laser ablation for prostate cancer in his practice. Dr. Parekattil first explains the importance of finding a safe method for treating localized prostate cancer, highlighting the prediction that 1.7 million men will be diagnosed with localized prostate cancer in 2040. He then analyzes two initial treatments currently in use, Active Surveillance and Radical Therapy, pinpoints issues with these methods, including the risk of missing growth and the onset of impotence and incontinence, and explains that the CLS-TRANBERG system combines the best of both treatments while avoiding their risks.

Dr. Parekattil explores additional benefits like quicker recovery, fewer side effects, and increased quality of life. He then highlights the system’s efficiency, noting that it can be performed in small, office-based settings. Dr. Parekattil further evaluates CLS-TRANBERG by listing image modalities it can be paired with, such as MRI and ultrasound. He notes that ultrasound even allows for real-time observation of tissue changes, increasing the operator’s ability to perform precise ablation. He also stresses the safety of the system by reviewing temperature probes and the avoidance of damaging surrounding organs.

Additionally, Dr. Parekattil emphasizes the lack of a need for a cooling loop in the CLS-TRANBERG system, adding ease to the procedure. He transitions to a discussion of the patient experience, presenting a patient testimonial that expresses a lack of discomfort and side effects. Dr. Parekattil completes his discussion by reviewing practice benefits and the consistent drop in PSA levels experienced by his patients after the CLS-TRANBERG procedure. Ultimately, Dr. Parekattil encourages urologists to consider this system as an option in initial prostate cancer treatment.